Literature DB >> 20407960

General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study.

A Jochmann, F Neubauer, D Miedinger, S Schafroth, M Tamm, J D Leuppi.   

Abstract

PRINCIPLES: Chronic obstructive pulmonary disease (COPD) is a major burden on patients and healthcare systems. Diagnosis and the management of COPD are often administered by general practitioners (GPs). This analysis investigated the adherence of GPs in Switzerland to the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) guidelines.
METHODS: As part of an ongoing investigation into the effect of GPs prescriptions on the clinical course of COPD, 139 GPs submitted a standardised questionnaire for each COPD patient recruited. Information requested included spirometric parameters, management and demographic data. Participating GPs were provided with and received instruction on a spirometer with automatic feedback on quality. Patients were grouped by the investigators into the GOLD COPD severity classifications, based on spirometric data provided. Data from the questionnaires were compared between the groups and management was compared with the recommendations of GOLD.
RESULTS: Of the 615 patients recruited, 44% did not fulfil GOLD criteria for COPD. Pulmonary rehabilitation was prescribed to 5% of all patients and less than one-third of patients exercised regularly. Less than half the patients in all groups used short-acting bronchodilators. Prescribing long-acting bronchodilators or inhaled corticosteroids conformed to GOLD guidelines in two-thirds of patients with GOLD stage III or IV disease, and approximately half of the less severe patients. Systemic steroids were inappropriately prescribed during stable disease in 6% of patients.
CONCLUSIONS: Adherence to GOLD (COPD) guidelines is low among GPs in Switzerland and COPD is often misdiagnosed or treated inappropriately. This is probably due to poor knowledge of disease definitions.

Entities:  

Year:  2010        PMID: 20407960     DOI: 10.4414/smw.2010.13053

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  30 in total

1.  Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities.

Authors:  Donald A Mahler; Dorothy L Keininger; Karen Mezzi; Robert Fogel; Donal Banerji
Journal:  Chronic Obstr Pulm Dis       Date:  2016-09-09

2.  Effects of GOLD-Adherent Prescribing on COPD Symptom Burden, Exacerbations, and Health Care Utilization in a Real-World Setting.

Authors:  David M Mannino; Tzy-Chyi Yu; Huanxue Zhou; Keiko Higuchi
Journal:  Chronic Obstr Pulm Dis       Date:  2015-06-19

3.  Use of Exhaled Nitric Oxide as a Biomarker in Diagnosis and Management of Chronic Obstructive Pulmonary Disease.

Authors:  Ahmed A Arif; Colin Mitchell
Journal:  J Prim Care Community Health       Date:  2015-12-30

Review 4.  Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions.

Authors:  Jeff D Overington; Yao C Huang; Michael J Abramson; Juliet L Brown; John R Goddard; Rayleen V Bowman; Kwun M Fong; Ian A Yang
Journal:  J Thorac Dis       Date:  2014-11       Impact factor: 2.895

5.  Simulation curriculum can improve medical student assessment and management of acute coronary syndrome during a clinical practice exam.

Authors:  Deborah J DeWaay; Matthew D McEvoy; Donna H Kern; Louise A Alexander; Paul J Nietert
Journal:  Am J Med Sci       Date:  2014-06       Impact factor: 2.378

6.  Missing potential opportunities to reduce repeat COPD exacerbations.

Authors:  Anne C Melzer; Laura M Feemster; Jane E Uman; David H Ramenofsky; David H Au
Journal:  J Gen Intern Med       Date:  2012-12-08       Impact factor: 5.128

7.  LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.

Authors:  Nanshan Zhong; Changzheng Wang; Xiangdong Zhou; Nuofu Zhang; Michael Humphries; Linda Wang; Chau Thach; Francesco Patalano; Donald Banerji
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-05

8.  Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.

Authors:  Shannon Cope; Matthias Kraemer; Jie Zhang; Gorana Capkun-Niggli; Jeroen P Jansen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-07-05

9.  The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.

Authors:  Guy Brusselle; David Price; Kevin Gruffydd-Jones; Marc Miravitlles; Dorothy L Keininger; Rebecca Stewart; Michael Baldwin; Rupert C Jones
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-15

10.  Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.

Authors:  Yogesh Suresh Punekar; Sarah H Landis; Keele Wurst; Hoa Le
Journal:  Respir Res       Date:  2015-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.